Cargando…

Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study

BACKGROUND: Cardiovascular disease (CVD) is one of the most important causes of mortality and morbidity in Iran. Secondary prevention of acute myocardial infarction (AMI) is necessary. The main aim of this cohort is evaluating clinical, paraclinical, management, and 5-year major events of the partic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadeghi, Masoumeh, Soleimani, Azam, Sarrafzadegan, Nizal, Askari, Mozhde, Nouri, Fatemeh, Masoumi, Gholamreza, Hassannejad, Razieh, Roohafza, Hamidreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133708/
https://www.ncbi.nlm.nih.gov/pubmed/35685820
http://dx.doi.org/10.22122/arya.v17i0.2375
_version_ 1784713628886237184
author Sadeghi, Masoumeh
Soleimani, Azam
Sarrafzadegan, Nizal
Askari, Mozhde
Nouri, Fatemeh
Masoumi, Gholamreza
Hassannejad, Razieh
Roohafza, Hamidreza
author_facet Sadeghi, Masoumeh
Soleimani, Azam
Sarrafzadegan, Nizal
Askari, Mozhde
Nouri, Fatemeh
Masoumi, Gholamreza
Hassannejad, Razieh
Roohafza, Hamidreza
author_sort Sadeghi, Masoumeh
collection PubMed
description BACKGROUND: Cardiovascular disease (CVD) is one of the most important causes of mortality and morbidity in Iran. Secondary prevention of acute myocardial infarction (AMI) is necessary. The main aim of this cohort is evaluating clinical, paraclinical, management, and 5-year major events of the participants in Isfahan, Iran. METHODS: All consecutive patients with AMI hospitalized in Chamran Hospital, Isfahan, during 1 year from march 2015 were recruited and followed for 5 years. ST-Elevation Myocardial Infarction Cohort Study (SEMI-CI) has been initiated as a longitudinal study to evaluate course of patients with AMI in Iran, adherence to evidence-based secondary prevention drug, and five-year events such as death, re-myocardial infarction (REMI), re-hospitalization, congestive heart failure (CHF), and referring to another procedure [percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), and resynchronization therapy]. RESULTS: A total of 867 patients with ST-elevation myocardial infarction (STEMI) with mean age of 60.91 ± 12.76 years were recruited. 705 (81.3%) subjects were men with mean age of 59.63 ± 12.59 years. 470 (54.2%) patients had anterior AMI (ant-AMI) and the rest had other types of AMI. The ejection fraction (EF) mean was 37.80 ± 11.74 percent. A total of 30 (3.5%) cases of AMI had not received reperfusion. 445 (51.4%) had primary PCI and 392 (45.2%) had thrombolysis at first revascularization strategy. In-hospital death occurred in 72 participants (8.3%). Drug during hospital included: at discharge, 767 (88.5%) received aspirin, 787 (90.7%) statin, 697 (80.4%) beta-blocker, and 480 (55.4%) angiotensin-converting enzyme (ACE) inhibitor. CONCLUSION: According to the best of our knowledge, it is among few cohorts in Eastern Mediterranean Region (EMR) in patients with AMI. This paper showed methodology of this study in patients with STEMI and its follow-up protocol. We can use this result in policy-making for improving secondary prevention strategies.
format Online
Article
Text
id pubmed-9133708
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-91337082022-06-08 Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study Sadeghi, Masoumeh Soleimani, Azam Sarrafzadegan, Nizal Askari, Mozhde Nouri, Fatemeh Masoumi, Gholamreza Hassannejad, Razieh Roohafza, Hamidreza ARYA Atheroscler Original Article BACKGROUND: Cardiovascular disease (CVD) is one of the most important causes of mortality and morbidity in Iran. Secondary prevention of acute myocardial infarction (AMI) is necessary. The main aim of this cohort is evaluating clinical, paraclinical, management, and 5-year major events of the participants in Isfahan, Iran. METHODS: All consecutive patients with AMI hospitalized in Chamran Hospital, Isfahan, during 1 year from march 2015 were recruited and followed for 5 years. ST-Elevation Myocardial Infarction Cohort Study (SEMI-CI) has been initiated as a longitudinal study to evaluate course of patients with AMI in Iran, adherence to evidence-based secondary prevention drug, and five-year events such as death, re-myocardial infarction (REMI), re-hospitalization, congestive heart failure (CHF), and referring to another procedure [percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), and resynchronization therapy]. RESULTS: A total of 867 patients with ST-elevation myocardial infarction (STEMI) with mean age of 60.91 ± 12.76 years were recruited. 705 (81.3%) subjects were men with mean age of 59.63 ± 12.59 years. 470 (54.2%) patients had anterior AMI (ant-AMI) and the rest had other types of AMI. The ejection fraction (EF) mean was 37.80 ± 11.74 percent. A total of 30 (3.5%) cases of AMI had not received reperfusion. 445 (51.4%) had primary PCI and 392 (45.2%) had thrombolysis at first revascularization strategy. In-hospital death occurred in 72 participants (8.3%). Drug during hospital included: at discharge, 767 (88.5%) received aspirin, 787 (90.7%) statin, 697 (80.4%) beta-blocker, and 480 (55.4%) angiotensin-converting enzyme (ACE) inhibitor. CONCLUSION: According to the best of our knowledge, it is among few cohorts in Eastern Mediterranean Region (EMR) in patients with AMI. This paper showed methodology of this study in patients with STEMI and its follow-up protocol. We can use this result in policy-making for improving secondary prevention strategies. Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences 2021-05 /pmc/articles/PMC9133708/ /pubmed/35685820 http://dx.doi.org/10.22122/arya.v17i0.2375 Text en © 2021 Isfahan Cardiovascular Research Center & Isfahan University of Medical Sciences https://creativecommons.org/licenses/by-nc/3.0/This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Sadeghi, Masoumeh
Soleimani, Azam
Sarrafzadegan, Nizal
Askari, Mozhde
Nouri, Fatemeh
Masoumi, Gholamreza
Hassannejad, Razieh
Roohafza, Hamidreza
Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study
title Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study
title_full Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study
title_fullStr Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study
title_full_unstemmed Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study
title_short Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study
title_sort background and design of a 5-year st elevation myocardial infarction cohort in isfahan, iran: semi-ci study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133708/
https://www.ncbi.nlm.nih.gov/pubmed/35685820
http://dx.doi.org/10.22122/arya.v17i0.2375
work_keys_str_mv AT sadeghimasoumeh backgroundanddesignofa5yearstelevationmyocardialinfarctioncohortinisfahaniransemicistudy
AT soleimaniazam backgroundanddesignofa5yearstelevationmyocardialinfarctioncohortinisfahaniransemicistudy
AT sarrafzadegannizal backgroundanddesignofa5yearstelevationmyocardialinfarctioncohortinisfahaniransemicistudy
AT askarimozhde backgroundanddesignofa5yearstelevationmyocardialinfarctioncohortinisfahaniransemicistudy
AT nourifatemeh backgroundanddesignofa5yearstelevationmyocardialinfarctioncohortinisfahaniransemicistudy
AT masoumigholamreza backgroundanddesignofa5yearstelevationmyocardialinfarctioncohortinisfahaniransemicistudy
AT hassannejadrazieh backgroundanddesignofa5yearstelevationmyocardialinfarctioncohortinisfahaniransemicistudy
AT roohafzahamidreza backgroundanddesignofa5yearstelevationmyocardialinfarctioncohortinisfahaniransemicistudy